Transient removal of CD46 is safe and increases B-cell depletion by rituximab in CD46 transgenic mice and macaques.
about
Preclinical safety, pharmacokinetics, pharmacodynamics, and biodistribution studies with Ad35K++ protein: a novel rituximab cotherapeutic.Protein engineering to target complement evasion in cancer.Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer.CD55 limits sensitivity to complement-dependent cytolysis triggered by heterologous expression of α-gal xenoantigen in colon tumor cells.Correlation between cellular expression of complement regulatory proteins with depletion and repopulation of B-lymphocytes in peripheral blood of patients with rheumatoid arthritis treated with rituximab.Recombinant Ad35 adenoviral proteins as potent modulators of human T cell activation.
P2860
Transient removal of CD46 is safe and increases B-cell depletion by rituximab in CD46 transgenic mice and macaques.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Transient removal of CD46 is s ...... transgenic mice and macaques.
@ast
Transient removal of CD46 is s ...... transgenic mice and macaques.
@en
type
label
Transient removal of CD46 is s ...... transgenic mice and macaques.
@ast
Transient removal of CD46 is s ...... transgenic mice and macaques.
@en
prefLabel
Transient removal of CD46 is s ...... transgenic mice and macaques.
@ast
Transient removal of CD46 is s ...... transgenic mice and macaques.
@en
P2093
P2860
P356
P1433
P1476
Transient removal of CD46 is s ...... transgenic mice and macaques.
@en
P2093
André Lieber
Audrey Baldessari
Diane Rocha
Douglas Woodle
Hongjie Wang
Ines Beyer
Jaclyn Bogue
Jonas Persson
Michael Gough
P2860
P304
P356
10.1038/MT.2012.212
P577
2012-10-23T00:00:00Z